IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
2023年9月26日 - 9:30PM
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company
focused on developing DNA-mediated immunotherapy and
next-generation vaccines, today announced the release of an
enterprise video that highlights the company’s mission, vision,
values, breakthroughs and technologies.
The video, which can be viewed on IMUNON's newly
relaunched website (www.IMUNON.com), provides an overview of the
company and its mission to develop innovative treatments that
harness the body’s natural mechanisms to generate safe, effective
and durable responses across a broad array of human diseases. It
was filmed in large part during the unveiling of IMUNON’s new
current Good Manufacturing Practices (cGMP) facility in the
Huntsville, Alabama campus of the AlphaHudson Institute for
Biotechnology. The facility is intended to enhance IMUNON’s control
over the quantities and costs of manufacturing non-viral DNA-based
materials used in its research and development activities. The
video continues with a discussion of IMUNON’s vision for the future
of immunotherapy, its values of innovation, collaboration and
patient-centricity, and its recent breakthroughs in the development
of DNA-based vaccines and therapeutics.
“We are proud to release our first-ever
enterprise video to share our story,” said Dr. Corinne Le Goff,
president and chief executive officer of IMUNON. “It provides an
excellent overview of our company as well as our vision for the
future of immunotherapy. We believe that this video will help to
raise awareness of our work and the potential of DNA-based
immunotherapy to address some of the most challenging diseases
facing humanity.”
The video features interviews with several
IMUNON scientists and executives who discuss the company’s
technology and its potential to revolutionize the treatment of
disease.
“We believe that DNA-based immunotherapy has the
potential to be a game-changer in the fight against disease,” said
Khursheed Anwer, Ph.D., executive vice president and chief
scientific officer of IMUNON. “Our non-viral technology has the
ability to generate powerful and durable immune responses, and we
are excited to explore its many benefits with an initial focus on
oncology and infectious diseases.”
The video concludes by highlighting IMUNON’s
commitment to advancing the field of immunotherapy and its goal of
making a meaningful difference in the lives of patients.
“We are passionate about developing innovative
treatments that can help patients live longer, healthier lives,”
added Le Goff. “We believe that DNA-based immunotherapy has the
potential to revolutionize the treatment of disease, and we are
excited to continue our work to bring medicines formulated with our
TheraPlas, PlaCCine, IndiPlas and FixPlas technologies to
patients.”
IMUNON's newly relaunched website provides a
view of the Company's medical technology platform and manufacturing
capabilities, as well as providing updates to the Company pipeline
and news and events.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlasTM,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine TM is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas TM, concerns the application of our DNA
technology to produce universal cancer vaccines, also called tumor
associated antigen cancer vaccines. The fourth modality, which is
in the discovery phase, IndiPlas TM, will focus on the development
of personalized cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine (IMNN-101) and a treatment for the Lassa
virus (IMNN-102). The Company has also initiated preclinical work
to develop a Trp2 tumor associated antigen cancer vaccine in
melanoma: IMNN-201. We will continue to leverage these modalities
and to advance the technological frontier of plasmid DNA to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024